Thursday, January 28, 2010

Rotateq® Suspected In "Failure To Thrive" Syndrome -- In Three Infant Cases: NEJM


A new report in The New England Journal of Medcine concludes that Merck's Rotateq® -- used to vaccinate against rotavirus -- when administered to immuno-deficient infants, was associated with severe dehydration and diarrhea in the patients. "These infections raise concerns regarding the safety of rotavirus vaccine in severely immuno-compromised patients." Rotateq vaccine is almost universally administered to infants in the United States, at present.

Per The Wall Street Journal, just now:

. . . .A report in this week's New England Journal of Medicine discusses the cases of three infants with severe combined immunodeficiency, or SCID, who developed dehydration and diarrhea after receiving a first or second dose of Rotateq, a vaccine made by Merck & Co. . . .

No comments: